The Thing You Could Do Regarding AZD4547 Starting Off In The Next 10-20 Minutes

Figure?1 shows the study inclusion and exclusion criteria. A total of 614 patients underwent http://www.selleckchem.com/products/MK-1775.html prostate whole-gland salvage cryotherapy within the COLD registry. Of these patients, 463 patients had received neoadjuvant, concomitant or adjuvant hormonal ablative therapy and were excluded. Of the remaining 151 patients, fewer than two consecutive post-salvage cryotherapy PSA measurements were available for 19 patients, who were thus excluded, which left 132 patients who constituted our study population. The primary endpoint was to determine the prognostic factors predicting the subsequent risk of biochemical failure using the validated Phoenix definition of biochemical failure (nadir + 2?ng/mL) [10, 13]. Descriptive statistics were reported using frequency distributions and percentages for categorical variables as well as mean and range of values for continuous variables. We used Kaplan�CMeier analysis for biochemical disease-free survival (bPFS) and a P value http://www.selleck.cn/products/azd4547.html another. The characteristics of the study population (N = 132) are shown in Table?1. The mean (range) age of our patients at time of diagnosis was 70.1 (46.0�C87.0) years. Most patients had an initial biopsy Gleason score http://www.selleckchem.com/products/AZD6244.html 6.2?ng/mL (4.9�C34.2%). The D'Amico risk group of patients at time of diagnosis was low in 18 (14%), intermediate in 82 (62%), and high in 32 (24%). The median (range) nadir PSA achieved after cryotherapy within our patient population was 0.17 (0�C33.9) ng/mL. Within the study population, a nadir PSA